Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy

Ann Rheum Dis. 2014 May;73(5):945-7. doi: 10.1136/annrheumdis-2013-204137. Epub 2013 Dec 13.
No abstract available

Keywords: Cytokines; DMARDs (biologic); Disease Activity; Rheumatoid Arthritis; Treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / blood*
  • Arthritis, Rheumatoid / drug therapy
  • Female
  • Humans
  • Interleukin-6 / blood
  • Luminescent Measurements
  • Male
  • Middle Aged
  • Molecular Targeted Therapy*
  • Receptors, Interleukin-6 / blood*
  • Remission Induction

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • IL6 protein, human
  • Interleukin-6
  • Receptors, Interleukin-6
  • tocilizumab